Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) is now available.
Hemogenyx Pharmaceuticals has announced the publication of a Prospectus related to the admission of new ordinary shares to the London Stock Exchange. This move involves the conversion of convertible loan notes and the exercise of warrants, with trading expected to commence on 24 November 2025. This development is significant for Hemogenyx as it enhances their market presence and potentially impacts their financial standing by increasing the number of shares available for trading.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing a platform technology for novel product development.
Average Trading Volume: 122,583
Technical Sentiment Signal: Buy
Current Market Cap: £47.39M
Find detailed analytics on HEMO stock on TipRanks’ Stock Analysis page.